TY - JOUR
T1 - Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations
AU - Sadler, Brooke
AU - Minard, Charles G.
AU - Haller, Gabe
AU - Gurnett, Christina A.
AU - O'Brien, Sarah H.
AU - Wheeler, Allison
AU - Jain, Shilpa
AU - Sharma, Mutka
AU - Zia, Ayesha
AU - Kulkarni, Roshni
AU - Mullins, Eric
AU - Ragni, Margaret V.
AU - Sidonio, Robert
AU - Dietrich, Jennifer E.
AU - Kouides, Peter A.
AU - Di Paola, Jorge
AU - Srivaths, Lakshmi
N1 - Publisher Copyright:
© 2022 American Society of Hematology. All rights reserved.
PY - 2022/1/25
Y1 - 2022/1/25
N2 - Adolescents with low von Willebrand factor (VWF) levels and heavy menstrual bleeding (HMB) experience significant morbidity. There is a need to better characterize these patients genetically and improve our understanding of the pathophysiology of bleeding. We performed whole-exome sequencing on 86 postmenarchal patients diagnosed with low VWF levels (30-50 IU/dL) and HMB and compared them with 660 in-house controls. We compared the number of rare stop-gain/stop-loss and rare ClinVar "pathogenic" variants between cases and controls, as well as performed gene burden and gene-set burden analyses. We found an enrichment in cases of rare stop-gain/stop-loss variants in genes involved in bleeding disorders and an enrichment of rare ClinVar "pathogenic" variants in genes involved in anemias. The 2 most significant genes in the gene burden analysis, CFB and DNASE2, are associated with atypical hemolytic uremia and severe anemia, respectively. VWF also surpassed exome-wide significance in the gene burden analysis (P = 7.31 x 1026). Gene-set burden analysis revealed an enrichment of rare nonsynonymous variants in cases in several hematologically relevant pathways. Further, common variants in FERMT2, a gene involved in the regulation of hemostasis and angiogenesis, surpassed genome-wide significance. We demonstrate that adolescents with HMB and low VWF have an excess of rare nonsynonymous and pathogenic variants in genes involved in bleeding disorders and anemia. Variants of variable penetrance in these genes may contribute to the spectrum of phenotypes observed in patients with HMB and could partially explain the bleeding phenotype. By identifying patients with HMB who possess these variants, we may be able to improve risk stratification and patient outcomes.
AB - Adolescents with low von Willebrand factor (VWF) levels and heavy menstrual bleeding (HMB) experience significant morbidity. There is a need to better characterize these patients genetically and improve our understanding of the pathophysiology of bleeding. We performed whole-exome sequencing on 86 postmenarchal patients diagnosed with low VWF levels (30-50 IU/dL) and HMB and compared them with 660 in-house controls. We compared the number of rare stop-gain/stop-loss and rare ClinVar "pathogenic" variants between cases and controls, as well as performed gene burden and gene-set burden analyses. We found an enrichment in cases of rare stop-gain/stop-loss variants in genes involved in bleeding disorders and an enrichment of rare ClinVar "pathogenic" variants in genes involved in anemias. The 2 most significant genes in the gene burden analysis, CFB and DNASE2, are associated with atypical hemolytic uremia and severe anemia, respectively. VWF also surpassed exome-wide significance in the gene burden analysis (P = 7.31 x 1026). Gene-set burden analysis revealed an enrichment of rare nonsynonymous variants in cases in several hematologically relevant pathways. Further, common variants in FERMT2, a gene involved in the regulation of hemostasis and angiogenesis, surpassed genome-wide significance. We demonstrate that adolescents with HMB and low VWF have an excess of rare nonsynonymous and pathogenic variants in genes involved in bleeding disorders and anemia. Variants of variable penetrance in these genes may contribute to the spectrum of phenotypes observed in patients with HMB and could partially explain the bleeding phenotype. By identifying patients with HMB who possess these variants, we may be able to improve risk stratification and patient outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85123521470&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021005118
DO - 10.1182/bloodadvances.2021005118
M3 - Article
C2 - 34807970
AN - SCOPUS:85123521470
SN - 2473-9529
VL - 6
SP - 420
EP - 428
JO - Blood Advances
JF - Blood Advances
IS - 2
ER -